MULTIPLE PRIMARY SYNCHRONOUS NEOPLASMS OF THE SIGMOID COLON AND BREAST IN COMBINATION WITH SPINAL CORD MENINGIOMA. CLINICAL CASE

The incidence of multiple primary oncological diseases ranges from 2.4% to 17%. The main causes of primary multiple diseases include factors related to the patient's lifestyle, environmental and genetic factors, as well as factors related to the comprehensive treatment of previously identified malignant diseases.

We demonstrate a clinical case of treatment of a patient with synchronous primary multiple cancer of the sigmoid colon and breast in combination with spinal cord meningioma. An interesting fact is the possible correlation between meningioma and breast cancer. Thus, the risk of meningioma in women who have had breast cancer and the risk of breast cancer in women with a history of meningioma is moderately increased (RR = 1.40-1.64 and 1.54, respectively). This two-way statistical association may be a consequence of common risk factors and a partial coincidence of gene-environmental interactions that determine carcinogenesis. Further research is needed to identify problems of prevention, screening, diagnosis, treatment and disease-free survival. It is important that patients diagnosed with cancer have information about possible late and long-term consequences of treatment and its symptoms, as well as possible signs of relapse and the appearance of secondary tumors. It is important that patients receiving treatment for malignant neoplasms follow the recommendations for cancer prevention and early detection, including smoking cessation, physical activity, nutrition and diet, a healthy weight and all standard cancer screening tests.

1. Copur M. S., Manapuram S. Multiple Primary Tumors Over a Lifetime. Oncology (Williston Park, NY). – 2019; 33.7.

2. Kaprin AD, Starinski VV. The state of oncological medical cervices for Russian population in 2016. P.A. Gertsen MSROI — the filial of FSBI NMRCR of the Ministry of Health of Russia Federation. M. 2017. 236 p. (In Russ.)

3. April Fritz Constance Percy Andrew Jack Kanagaratnam Shanmugaratnam Leslie Sobin D Max Parkin Sharon Whelan. International classification of diseases for oncology (ICD-O) – 3rd edition, 1st revision. WHO, 2013. 252 p.

4. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019 June 11. https://doi.org/10.3322/caac.21565

5. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012 Oct 20;30(30):3734-45. https://doi.org/ 10.1200/JCO.2012.41.8681

6. Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017 May 2;2(2):e000172. https://doi.org/ 10.1136/esmoopen-2017-000172

7. Coyte A, Morrison DS, McLoone P. Second primary cancer risk--the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. BMC Cancer. 2014;14:272. https://doi.org/10.1186/1471-2407-14-272

8. Amer MH. Multiple neoplasms, single primaries, and patient survival. Cancer Manag Res. 2014;6:119-34. https://doi.org/10.2147/CMAR.S57378

9. Scott LC, Kuo TM, Il'yasova D, Mobley LR. Geospatial analysis of multiple cancers in individuals in the US, 2004-2014. Ann Cancer Epidemiol. 2021 Mar;5:2. https://doi.org/10.21037/ace-19-40

10. Zheng G, Sundquist K, Sundquist J, Chen T, Försti A, Hemminki A, Hemminki K. Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer. Clin Epidemiol. 2021 Jul 2;13:515-525. https://doi.org/10.2147/CLEP.S304332

11. Fraumeni JF, Curtis RE, Edwards BK, Tucker MA. Introduction. In: Curtis RE, Freedman DM, Ron E. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. NIH Publ. 05-5302. Bethesda, MD: National Cancer Institute; 2006.

12. Waespe N, Belle FN, Redmond S, Schindera C, Spycher BD, Rössler J, Ansari M, Kuehni CE; Swiss Paediatric Oncology Group (SPOG). Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer - A national cohort study. Eur J Cancer. 2021 Mar;145:71-80. https://doi.org/ 10.1016/j.ejca.2020.11.042

13. Begg CB, Zhang ZF, Sun M, Herr HW, Schantz SP. Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. Am J Epidemiol. 1995;142:653-65. https://doi.org/10.1093/oxfordjournals.aje.a117689

14. Sung H, Hyun N, Leach CR, Yabroff KR, Jemal A. Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of AdultOnset Cancers in the United States. JAMA. 2020 Dec 22;324(24):2521-2535. https://doi.org/ 10.1001/jama.2020.23130

15. Forjaz de Lacerda G, Howlader N, Mariotto AB. Differences in Cancer Survival with Relative versus Cause-Specific Approaches: An Update Using More Accurate Life Tables. Cancer Epidemiol Biomarkers Prev. 2019 Sep;28(9):1544-1551. https://doi.org/ 10.1158/1055-9965.EPI-19-0125

16. Montiel Ishino FA, Odame EA, Villalobos K, Liu X, Salmeron B, Mamudu H, Williams F. A National Study of Colorectal Cancer Survivorship Disparities: A Latent Class Analysis Using SEER (Surveillance, Epidemiology, and End Results) Registries. Front Public Health. 2021 Feb 25;9:628022. https://doi.org/10.3389/fpubh.2021.628022

17. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med. 2005 May;46(5):752-7.

18. Miyazaki T, Sohda M, Higuchi T, et al. Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer. Anticancer Res. 2014;34

19. McNeill KA. Epidemiology of Brain Tumors. Neurol Clin. 2016 Nov;34(4):981-998. https://doi.org/10.1016/j.ncl.2016.06.014

20. Baldi I, Engelhardt J, Bonnet C, Bauchet L, Berteaud E, Grüber A, Loiseau H. Epidemiology of meningiomas. Neurochirurgie. 2018 Mar;64(1):5-14. https:// doi.org/10.1016/j.neuchi.2014.05.006

21. Ketter R, Rahnenführer J, Henn W, Kim YJ, Feiden W, Steudel WI, Zang KD, Urbschat S. Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas. Neurosurgery. 2008 Jan; 62(1):61-9; discussion 69-70. https://doi.org/10.1227/01.NEU.0000311062.72626.D6

22. Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, Parsa AT, Yang I. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus. 2011 May;30(5):E6. https://doi.org/10.3171/2011.2.FOCUS1116

23. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kiliç T, Lifton RP, Noonan JP, Yasuno K, Günel M. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013 Mar 1;339(6123):1077-80. https://doi.org/ 10.1126/science.1233009

24. Kerr K, Qualmann K, Esquenazi Y, Hagan J, Kim DH. Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease. Neurosurgery. 2018 Dec 1;83(6):1107-1118. https://doi.org/ 10.1093/neuros/nyy121

25. Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer. 2002 Mar 15;94(6):1626-35. https://doi.org/ 10.1002/cncr.10410